Pharmaceutical - Johnson & Johnson, simeprevir

Filter

Popular Filters

Positive new Ph III data from once-daily simeprevir presented at APASL

18-03-2014

Encouraging new Phase III data for the once-daily protease inhibitor simeprevir (trade name Olysio in…

Anti-viralsJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalResearchsimeprevir

AASLD meeting highlights: Gilead’s sofosbuvir, Janssen’s simeprevir and Boehringer’s faldaprevir

03-11-2013

Among research results released at this week at the 64th Annual Meeting of the American Association for…

Anti-viralsBiotechnologyBoehringer IngelheimfaldaprevirGilead SciencesJanssenJohnson & JohnsonPharmaceuticalResearchsimeprevirsofosbuvir

Unanimous FDA panel backing for Janssen’s simeprevir for hep C

Unanimous FDA panel backing for Janssen’s simeprevir for hep C

25-10-2013

Janssen announced yesterday that the FDA's Antiviral Drugs Advisory Committee unanimously recommended…

Anti-viralsJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevir

Janssen files for European approval of hep C candidate simeprevir

25-04-2013

Janssen-Cilag International, a European subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ),…

Anti-viralsBiotechnologyEuropeJanssen-CilagJohnson & JohnsonPharmaceuticalRegulationsimeprevir

Highlights of presentations from Bristol-Myers, J&J, Gilead and AbbVie at EASL meeting

24-04-2013

Among a number of drug and biotech majors planning to present at the 2013 annual meeting of the European…

AbbVieAnti-viralsasunaprevirBiotechnologyBristol-Myers SquibbdaclatasvirGilead SciencesJohnson & JohnsonPharmaceuticalResearchsimeprevirsofosbuvir

Medivir/J&J, Merck & Co and Bristol-Myers to present at Int Liver Congress

09-04-2013

Swedish infectious disease drug developer Medivir AB (OMX: MVIR) and US partner Johnson & Johnson (NYSE:…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirJohnson & JohnsonMedivirMerck & CoMK-5172PharmaceuticalResearchsimeprevirVaniprevirVictrelis

Janssen gains FDA approval of Invokana for type 2 diabetes; files simeprevir NDA

02-04-2013

There were a couple of good news items for Johnson & Johnson (NYSE: JNJ) unit Janssen Pharmaceuticals…

Anti-viralsDiabetesInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevirTMC435

Vertex links with Janssen and GlaxoSmithKline for combo trials with its VX-135 for hepatitis C

02-11-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Pharmaceuticals unit has entered into a…

Anti-viralsBiotechnologyGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonPharmaceuticalResearchsimeprevirVertexVX-135

Parexel

Parexel

Back to top